Galectin Therapeutics (GALT) PT Raised to $8 at Roth Capital
Tweet Send to a Friend
Roth Capital raised its price target on Galectin Therapeutics (NASDAQ: GALT) to $8.00 (from $3.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
